Literature DB >> 29097696

Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain.

Christopher S Anderson1, Sandra Ortega1, Francisco A Chaves1, Amelia M Clark1, Hongmei Yang2, David J Topham3, Marta L DeDiego4.   

Abstract

The induction of antibodies specific for the influenza HA protein stalk domain is being pursued as a universal strategy against influenza virus infections. However, little work has been done looking at natural or induced antigenic variability in this domain and the effects on viral fitness. We analyzed human H1 HA head and stalk domain sequences and found substantial variability in both, although variability was highest in the head region. Furthermore, using human immune sera from pandemic A/California/04/2009 immune subjects and mAbs specific for the stalk domain, viruses were selected in vitro containing mutations in both domains that partially contributed to immune evasion. Recombinant viruses encoding amino acid changes in the HA stalk domain replicated well in vitro, and viruses incorporating two of the stalk mutations retained pathogenicity in vivo. These findings demonstrate that the HA protein stalk domain can undergo limited drift under immune pressure and the viruses can retain fitness and virulence in vivo, findings which are important to consider in the context of vaccination targeting this domain.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29097696      PMCID: PMC5668287          DOI: 10.1038/s41598-017-14931-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  63 in total

1.  Linker and/or transmembrane regions of influenza A/Group-1, A/Group-2, and type B virus hemagglutinins are packed differently within trimers.

Authors:  Larisa V Kordyukova; Marina V Serebryakova; Anton A Polyansky; Ekaterina A Kropotkina; Andrei V Alexeevski; Michael Veit; Roman G Efremov; Irina Yu Filippova; Lyudmila A Baratova
Journal:  Biochim Biophys Acta       Date:  2011-03-21

2.  Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs.

Authors:  Zhongying Chen; Weijia Wang; Helen Zhou; Amorsolo L Suguitan; Cindy Shambaugh; Lomi Kim; Jackie Zhao; George Kemble; Hong Jin
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

3.  Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.

Authors:  James R R Whittle; Adam K Wheatley; Lan Wu; Daniel Lingwood; Masaru Kanekiyo; Steven S Ma; Sandeep R Narpala; Hadi M Yassine; Gregory M Frank; Jonathan W Yewdell; Julie E Ledgerwood; Chih-Jen Wei; Adrian B McDermott; Barney S Graham; Richard A Koup; Gary J Nabel
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

Review 4.  Emergence and pandemic potential of swine-origin H1N1 influenza virus.

Authors:  Gabriele Neumann; Takeshi Noda; Yoshihiro Kawaoka
Journal:  Nature       Date:  2009-06-18       Impact factor: 49.962

5.  A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.

Authors:  Gene S Tan; Florian Krammer; Dirk Eggink; Alita Kongchanagul; Thomas M Moran; Peter Palese
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

6.  A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.

Authors:  Nicola Clementi; Donata De Marco; Nicasio Mancini; Laura Solforosi; Guisella J Moreno; Larisa V Gubareva; Vasiliy Mishin; Andrea Di Pietro; Elisa Vicenzi; Antonio G Siccardi; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

7.  Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.

Authors:  Marta L DeDiego; Christopher S Anderson; Hongmei Yang; Jeanne Holden-Wiltse; Theresa Fitzgerald; John J Treanor; David J Topham
Journal:  Immunology       Date:  2016-03-30       Impact factor: 7.397

8.  Novel Sequence-Based Mapping of Recently Emerging H5NX Influenza Viruses Reveals Pandemic Vaccine Candidates.

Authors:  Christopher S Anderson; Marta L DeDiego; Juilee Thakar; David J Topham
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

Review 9.  A review of vaccine research and development: human acute respiratory infections.

Authors:  Marc P Girard; Thomas Cherian; Yuri Pervikov; Marie Paule Kieny
Journal:  Vaccine       Date:  2005-08-03       Impact factor: 3.641

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  25 in total

1.  Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses.

Authors:  Nicholas C Wu; Andrew J Thompson; Juhye M Lee; Wen Su; Britni M Arlian; Jia Xie; Richard A Lerner; Hui-Ling Yen; Jesse D Bloom; Ian A Wilson
Journal:  Science       Date:  2020-06-19       Impact factor: 47.728

2.  Deep sequencing of 2009 influenza A/H1N1 virus isolated from volunteer human challenge study participants and natural infections.

Authors:  Yongli Xiao; Jae-Keun Park; Stephanie Williams; Mitchell Ramuta; Adriana Cervantes-Medina; Tyler Bristol; Sarah Smith; Lindsay Czajkowski; Alison Han; John C Kash; Matthew J Memoli; Jeffery K Taubenberger
Journal:  Virology       Date:  2019-06-13       Impact factor: 3.616

Review 3.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

4.  Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.

Authors:  Ericka Kirkpatrick; Carole Henry; Meagan McMahon; Kaijun Jiang; Shirin Strohmeier; Harm van Bakel; Patrick C Wilson; Florian Krammer
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

5.  Crowd on a Chip: Label-Free Human Monoclonal Antibody Arrays for Serotyping Influenza.

Authors:  Hanyuan Zhang; Carole Henry; Christopher S Anderson; Aitor Nogales; Marta L DeDiego; Joseph Bucukovski; Luis Martinez-Sobrido; Patrick C Wilson; David J Topham; Benjamin L Miller
Journal:  Anal Chem       Date:  2018-07-20       Impact factor: 6.986

6.  Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.

Authors:  Jae-Keun Park; Yongli Xiao; Mitchell D Ramuta; Luz Angela Rosas; Sharon Fong; Alexis M Matthews; Ashley D Freeman; Monica A Gouzoulis; Natalia A Batchenkova; Xingdong Yang; Kelsey Scherler; Li Qi; Susan Reed; Rani Athota; Lindsay Czajkowski; Alison Han; David M Morens; Kathie-Anne Walters; Matthew J Memoli; John C Kash; Jeffery K Taubenberger
Journal:  Nat Med       Date:  2020-06-29       Impact factor: 53.440

7.  Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model.

Authors:  Alison Han; Lindsay Czajkowski; Luz Angela Rosas; Adriana Cervantes-Medina; Yongli Xiao; Monica Gouzoulis; Keith Lumbard; Sally Hunsberger; Susan Reed; Rani Athota; Holly Ann Baus; Amy Lwin; Jerald Sadoff; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

8.  The 2009 Pandemic H1N1 Hemagglutinin Stalk Remained Antigenically Stable after Circulating in Humans for a Decade.

Authors:  Shannon R Christensen; Emily T Martin; Joshua G Petrie; Arnold S Monto; Scott E Hensley
Journal:  J Virol       Date:  2022-05-19       Impact factor: 6.549

Review 9.  Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.

Authors:  Suzanne L Epstein
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

10.  How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin.

Authors:  Michael B Doud; Juhye M Lee; Jesse D Bloom
Journal:  Nat Commun       Date:  2018-04-11       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.